{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:51:49Z","timestamp":1794073909475,"version":"4.8.0"},"reference-count":41,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"792","content-domain":{"domain":["www.science.org"],"crossmark-restriction":true},"short-container-title":["Sci. Transl. Med."],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:p>\n                    Metabotropic glutamate receptor 5 (mGluR5) is involved in cocaine reward processing and addiction. Preclinical studies suggest that blocking this receptor inhibits cocaine self-administration and seeking behavior in rodents. We assessed a selective noncompetitive antagonist of mGluR5 called mavoglurant in a phase 2 randomized, placebo-controlled clinical trial of 68 adults with cocaine use disorder. Study participants were randomly assigned in a 1:1 ratio to an up-titrating schedule of oral mavoglurant twice daily up to 200 mg for 98 days or placebo. The primary end point was the proportion of cocaine use days over the treatment period assessed by a retrospective self-report using Timeline Followback. Secondary end points were urine analysis of the cocaine metabolite benzoylecgonine and alcohol use measured by Timeline Followback assessment. Exploratory end points included testing for cocaine and alcohol metabolites in hair samples. The posterior probability of mavoglurant reducing cocaine use at the end of treatment was \u226599.0% for a treatment difference\u00a0&lt;0 and\u00a0\u226536.6% for a treatment difference\u00a0&lt;\u221210%. The difference between mavoglurant and placebo was also assessed using analysis of covariance (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.021). Urine benzoylecgonine concentration was lower in the mavoglurant-treated group versus placebo (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.025); there was reduced alcohol consumption in the treatment group (\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00.072). Seventy-six percent (randomized set) and 79% (safety analysis set) of patients completed the final treatment visit. Adverse events in the treatment group were headache, dizziness, and nausea. In this small and short trial, mavoglurant reduced cocaine and alcohol use in patients with chronic cocaine use disorder.\n                  <\/jats:p>","DOI":"10.1126\/scitranslmed.adi4505","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T16:32:02Z","timestamp":1743611522000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark","source":"Crossref","is-referenced-by-count":10,"title":["Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial"],"prefix":"10.1126","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2427-9884","authenticated-orcid":true,"given":"Baltazar","family":"Gomez-Mancilla","sequence":"first","affiliation":[{"name":"Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1552-5822","authenticated-orcid":true,"given":"Kenneth M.","family":"D\u00fcrsteler","sequence":"additional","affiliation":[{"name":"Center for Addictive Disorders, Department of Psychiatry, Psychiatric Hospital, University of Basel, Basel, Switzerland."},{"name":"Center for Addictive Disorders, Department of Adult Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-0331","authenticated-orcid":true,"given":"Marc","family":"Vogel","sequence":"additional","affiliation":[{"name":"Center for Addictive Disorders, Department of Psychiatry, Psychiatric Hospital, University of Basel, Basel, Switzerland."},{"name":"Psychiatric Services of Thurgovia, Psychiatric Hospital M\u00fcnsterlingen, M\u00fcnsterlingen, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5830-1971","authenticated-orcid":true,"given":"Marcus","family":"Herdener","sequence":"additional","affiliation":[{"name":"Center for Addictive Disorders, Department of Adult Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-4761","authenticated-orcid":true,"given":"Marta","family":"Torrens","sequence":"additional","affiliation":[{"name":"Addiction Research Group, Hospital del Mar Medical Research Institute, Barcelona, Spain."},{"name":"Pompeu Fabra University, University of Vic-Central de Catalunya, and Red de investigaci\u00f3n en Atenci\u00f3n Primaria de Adicciones (RIAPAd), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8811-6937","authenticated-orcid":true,"given":"Bartolom\u00e9 P.","family":"G\u00e1lvez","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Universidad Miguel Hern\u00e1ndez, Edificio Muhammad Al-Shafra, Campus de San Juan, Alicante, Spain."},{"name":"Addictive Behaviors Unit, Hospital Universitario San Juan, Alicante, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7130-981X","authenticated-orcid":true,"given":"Antoni","family":"Gual","sequence":"additional","affiliation":[{"name":"Addictions Unit, Psychiatry Department, Neurosciences Institute, Hospital Cl\u00ednic, IDIBAPS, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-2009","authenticated-orcid":true,"given":"Ricardo M.","family":"Corral","sequence":"additional","affiliation":[{"name":"University of Buenos Aires, Buenos Aires, Argentina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7156-1491","authenticated-orcid":true,"given":"Enrique I.","family":"Kuper","sequence":"additional","affiliation":[{"name":"Centro Neurobiol\u00f3gico y de Stress Traum\u00e1tico-Biopsychomedical Research Group, Buenos Aires, Argentina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0488-9855","authenticated-orcid":true,"given":"Daniel L.","family":"Mosca","sequence":"additional","affiliation":[{"name":"Instituto Nacional Psicopatologia, Buenos Aires, Argentina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7881-206X","authenticated-orcid":true,"given":"Swati","family":"Dumitras","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5773-091X","authenticated-orcid":true,"given":"Nicole","family":"Pezous","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2448-5391","authenticated-orcid":true,"given":"Maria","family":"Berkheimer","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3913-9867","authenticated-orcid":true,"given":"Ela","family":"Walker","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3878-8522","authenticated-orcid":true,"given":"Fabrizio","family":"Gasparini","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0458-3931","authenticated-orcid":true,"given":"Jang-Ho","family":"Cha","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research, Cambridge, MA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2950-1161","authenticated-orcid":true,"given":"Ricardo","family":"Dolmetsch","sequence":"additional","affiliation":[{"name":"Novartis Biomedical Research, Cambridge, MA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","unstructured":"United Nations Office on Drugs and Crime Global Report on Cocaine 2023\u2014Local Dynamics Global Challenges (United Nations Publications 2023)."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-2069-2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/adb.12086","article-title":"A novel mGluR5 antagonist, MFZ 10-7, inhibits cocaine-taking and cocaine-seeking behavior in rats","volume":"19","author":"Keck T. M.","year":"2014","unstructured":"T. M. Keck, M. F. Zou, G. H. Bi, H. Y. Zhang, X. F. Wang, H. J. Yang, R. Srivastava, E. L. Gardner, Z. X. Xi, A. H. Newman, A novel mGluR5 antagonist, MFZ 10-7, inhibits cocaine-taking and cocaine-seeking behavior in rats. Addict. Biol. 19, 195\u2013209 (2014).","journal-title":"Addict. Biol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bbr.2009.03.039","article-title":"Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking","volume":"202","author":"Kumaresan V.","year":"2009","unstructured":"V. Kumaresan, M. Yuan, J. Yee, K. R. Famous, S. M. Anderson, H. D. Schmidt, R. C. Pierce, Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking. Behav. Brain Res. 202, 238\u2013244 (2009).","journal-title":"Behav. Brain Res."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1038\/s41598-018-22087-1","article-title":"mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism","volume":"8","author":"Li X.","year":"2018","unstructured":"X. Li, X.-Q. Peng, C. J. Jordan, J. Li, G.-H. Bi, Y. He, H.-J. Yang, H.-Y. Zhang, E. L. Gardner, Z.-X. Xi, mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism. Sci. Rep. 8, 3686 (2018).","journal-title":"Sci. Rep."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nn0901-873","article-title":"Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice","volume":"4","author":"Chiamulera C.","year":"2001","unstructured":"C. Chiamulera, M. P. Epping-Jordan, A. Zocchi, C. Marcon, C. Cottiny, S. Tacconi, M. Corsi, F. Orzi, F. Conquet, Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 4, 873\u2013874 (2001).","journal-title":"Nat. Neurosci."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1038\/s41380-020-0828-z","article-title":"Impaired glutamate homeostasis in the nucleus accumbens in human cocaine addiction","volume":"26","author":"Engeli E. J. E.","year":"2021","unstructured":"E. J. E. Engeli, N. Zoelch, A. Hock, C. Nordt, L. M. Hulka, M. Kirschner, M. Scheidegger, F. Esposito, M. R. Baumgartner, A. Henning, E. Seifritz, B. B. Quednow, M. Herdener, Impaired glutamate homeostasis in the nucleus accumbens in human cocaine addiction. Mol. Psychiatry 26, 5277\u20135285 (2021).","journal-title":"Mol. Psychiatry"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2014.09.033"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"117785","DOI":"10.1016\/j.neuroimage.2021.117785","article-title":"Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers","volume":"230","author":"Streffer J.","year":"2021","unstructured":"J. Streffer, V. Treyer, A. Buck, S. M. Ametamey, M. Blagoev, R. P. Maguire, A. Gautier, Y. P. Auberson, M. E. Schmidt, I. T. Vranesic, B. Gomez-Mancilla, F. Gasparini, Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers. Neuroimage 230, 117785 (2021).","journal-title":"Neuroimage"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.857400"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12325-016-0468-5","article-title":"Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: A proof-of-concept, randomized, placebo-controlled, phase 2 study","volume":"34","author":"Rutrick D.","year":"2017","unstructured":"D. Rutrick, D. J. Stein, G. Subramanian, B. Smith, M. Fava, G. Hasler, J. H. Cha, F. Gasparini, T. Donchev, M. Ocwieja, D. Johns, B. Gomez-Mancilla, Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: A proof-of-concept, randomized, placebo-controlled, phase 2 study. Adv. Ther. 34, 524\u2013541 (2017).","journal-title":"Adv. Ther."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","article-title":"AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials","volume":"26","author":"Berg D.","year":"2011","unstructured":"D. Berg, J. Godau, C. Trenkwalder, K. Eggert, I. Csoti, A. Storch, H. Huber, M. Morelli-Canelo, M. Stamelou, V. Ries, M. Wolz, C. Schneider, T. D. Paolo, F. Gasparini, S. Hariry, M. Vandemeulebroecke, W. Abi-Saab, K. Cooke, D. Johns, B. Gomez-Mancilla, AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials. Mov. Disord. 26, 1243\u20131250 (2011).","journal-title":"Mov. Disord."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/mds.26174","article-title":"A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington\u2019s disease","volume":"30","author":"Reilmann R.","year":"2015","unstructured":"R. Reilmann, M. L. Rouzade-Dominguez, C. Saft, S. D. Sussmuth, J. Priller, A. Rosser, H. Rickards, L. Schols, N. Pezous, F. Gasparini, D. Johns, G. B. Landwehrmeyer, B. Gomez-Mancilla, A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington\u2019s disease. Mov. Disord. 30, 427\u2013431 (2015).","journal-title":"Mov. Disord."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"16970","DOI":"10.1038\/s41598-018-34978-4","article-title":"Mavoglurant in fragile X syndrome: Results of two open-label, extension trials in adults and adolescents","volume":"8","author":"Hagerman R.","year":"2018","unstructured":"R. Hagerman, S. Jacquemont, E. Berry-Kravis, V. D. Portes, A. Stanfield, B. Koumaras, G. Rosenkranz, A. Murgia, C. Wolf, G. Apostol, F. von Raison, Mavoglurant in fragile X syndrome: Results of two open-label, extension trials in adults and adolescents. Sci. Rep. 8, 16970 (2018).","journal-title":"Sci. Rep."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/mds.25561","article-title":"AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study","volume":"28","author":"Stocchi F.","year":"2013","unstructured":"F. Stocchi, O. Rascol, A. Destee, N. Hattori, R. A. Hauser, A. E. Lang, W. Poewe, M. Stacy, E. Tolosa, H. Gao, J. Nagel, M. Merschhemke, A. Graf, C. Kenney, C. Trenkwalder, AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov. Disord. 28, 1838\u20131846 (2013).","journal-title":"Mov. Disord."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1037\/a0030992","article-title":"Reliability of the Timeline Follow back for cocaine, cannabis, and cigarette use","volume":"28","author":"Robinson S. M.","year":"2014","unstructured":"S. M. Robinson, L. C. Sobell, M. B. Sobell, G. I. Leo, Reliability of the Timeline Follow back for cocaine, cannabis, and cigarette use. Psychol. Addict. Behav. 28, 154\u2013162 (2014).","journal-title":"Psychol. Addict. Behav."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2515"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.10.034"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/npp.2017.49","article-title":"The nucleus accumbens and ketamine treatment in major depressive disorder","volume":"42","author":"Abdallah C. G.","year":"2017","unstructured":"C. G. Abdallah, A. Jackowski, R. Salas, S. Gupta, J. R. Sato, X. Mao, J. D. Coplan, D. C. Shungu, S. J. Mathew, The nucleus accumbens and ketamine treatment in major depressive disorder. Neuropsychopharmacology 42, 1739\u20131746 (2017).","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1719014115"},{"key":"e_1_3_2_22_2","first-page":"193","article-title":"El modulador alost\u00e9rico negativo de los mGluR5, MPEP, potencia la reinstauraci\u00f3n de la preferencia condicionada inducida con priming de coca\u00edna","volume":"32","author":"Manzanedo C.","year":"2020","unstructured":"C. Manzanedo, A. Mateos-Garc\u00eda, J. Mi\u00f1arro, M. C. Arenas, El modulador alost\u00e9rico negativo de los mGluR5, MPEP, potencia la reinstauraci\u00f3n de la preferencia condicionada inducida con priming de coca\u00edna. Adicciones 32, 193\u2013201 (2020).","journal-title":"Adicciones"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/aps.2014.93","article-title":"Blockade of mGluR5 in the nucleus accumbens shell but not core attenuates heroin seeking behavior in rats","volume":"35","author":"Lou Z.-z.","year":"2014","unstructured":"Z.-z. Lou, L.-h. Chen, H.-f. Liu, L.-m. Ruan, W.-h. Zhou, Blockade of mGluR5 in the nucleus accumbens shell but not core attenuates heroin seeking behavior in rats. Acta Pharmacol. Sin. 35, 1485\u20131492 (2014).","journal-title":"Acta Pharmacol. Sin."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1358\/dnp.2004.17.4.829052","article-title":"mGlu5 receptor antagonists: A novel class of anxiolytics?","volume":"17","author":"Spooren W.","year":"2004","unstructured":"W. Spooren, F. Gasparini, mGlu5 receptor antagonists: A novel class of anxiolytics? Drug News Perspect. 17, 251\u2013257 (2004).","journal-title":"Drug News Perspect."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.10.022"},{"key":"e_1_3_2_26_2","unstructured":"European Medicines Agency Guideline on the development of medicinal products for the treatment of alcohol dependence. EMEA\/CHMP\/EWP\/20097\/2008 (EMA 2010)."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003088-199936060-00004","article-title":"Drug interactions with tobacco smoking. An update","volume":"36","author":"Zevin S.","year":"1999","unstructured":"S. Zevin, N. L. Benowitz, Drug interactions with tobacco smoking. An update. Clin. Pharmacokinet. 36, 425\u2013438 (1999).","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.050716"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.2008.19.3995","article-title":"Overcoming CYP1A1\/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers","volume":"27","author":"Hughes A. N.","year":"2009","unstructured":"A. N. Hughes, M. E. R. O\u2019Brien, W. J. Petty, J. B. Chick, E. Rankin, P. J. Woll, D. Dunlop, M. Nicolson, R. Boinpally, J. Wolf, A. Price, Overcoming CYP1A1\/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J. Clin. Oncol. 27, 1220\u20131226 (2009).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cpr.2013.07.007","article-title":"Drop-out from addiction treatment: A systematic review of risk factors","volume":"33","author":"Brorson H.","year":"2013","unstructured":"H. Brorson, E. Arnevik, K. Rand, F. Duckert, Drop-out from addiction treatment: A systematic review of risk factors. Clin. Psychol. Rev. 33, 1010\u20131024 (2013).","journal-title":"Clin. Psychol. Rev."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1940-0640-9-8","article-title":"Randomized clinical trial of the effects of screening and brief intervention for illicit drug use: The Life Shift\/Shift Gears study","volume":"9","author":"Woodruff S. I.","year":"2014","unstructured":"S. I. Woodruff, J. D. Clapp, K. Eisenberg, C. McCabe, M. Hohman, A. M. Shillington, C. B. Sise, E. M. Castillo, T. C. Chan, M. J. Sise, J. Gareri, Randomized clinical trial of the effects of screening and brief intervention for illicit drug use: The Life Shift\/Shift Gears study. Addict. Sci. Clin. Pract. 9, 8 (2014).","journal-title":"Addict. Sci. Clin. Pract."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1526-4637.2006.00255.x","article-title":"Mechanisms of prescription drug diversion among drug-involved club- and street-based populations","volume":"8","author":"Inciardi J. A.","year":"2007","unstructured":"J. A. Inciardi, H. L. Surratt, S. P. Kurtz, T. J. Cicero, Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med. 8, 171\u2013183 (2007).","journal-title":"Pain Med."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1472-8206.2011.00950.x","article-title":"r\u00e9seau des CEIPs, Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey","volume":"26","author":"Frauger E.","year":"2012","unstructured":"E. Frauger, S. Nordmann, V. Orleans, V. Pradel, V. Pauly, X. Thirion, J. Micallef, r\u00e9seau des CEIPs, Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey. Fundam. Clin. Pharmacol. 26, 549\u2013556 (2012).","journal-title":"Fundam. Clin. Pharmacol."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1087054713493321","article-title":"Nonmedical use of prescription ADHD stimulant medications among adults in a substance abuse treatment population: Early findings from the NAVIPPRO surveillance system","volume":"19","author":"Cassidy T. A.","year":"2015","unstructured":"T. A. Cassidy, E. C. McNaughton, S. Varughese, L. Russo, M. Zulueta, S. F. Butler, Nonmedical use of prescription ADHD stimulant medications among adults in a substance abuse treatment population: Early findings from the NAVIPPRO surveillance system. J. Atten. Disord. 19, 275\u2013283 (2015).","journal-title":"J. Atten. Disord."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/archpsyc.1994.03950010008002","article-title":"Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity survey","volume":"51","author":"Kessler R. C.","year":"1994","unstructured":"R. C. Kessler, K. A. McGonagle, S. Zhao, C. B. Nelson, M. Hughes, S. Eshleman, H.-U. Wittchen, K. S. Kendler, Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the national comorbidity survey. Arch. Gen. Psychiatry 51, 8\u201319 (1994).","journal-title":"Arch. Gen. Psychiatry"},{"key":"e_1_3_2_36_2","unstructured":"Substance Abuse and Mental Health Services Administration Results from the 2012 National Survey on Drug Use and Health: Summary of national findings (NSDUH series H-46 HHS publication no. 13-4795 US Department of Health and Human Services Substance Abuse and Mental Health Services Administration 2013)."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jamapsychiatry.2013.2295","article-title":"Topiramate for the treatment of cocaine addiction: A randomized clinical trial","volume":"70","author":"Johnson B. A.","year":"2013","unstructured":"B. A. Johnson, N. Ait-Daoud, X.-Q. Wang, J. K. Penberthy, M. A. Javors, C. Seneviratne, L. Liu, Topiramate for the treatment of cocaine addiction: A randomized clinical trial. JAMA Psychiatry 70, 1338\u20131346 (2013).","journal-title":"JAMA Psychiatry"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pbb.2019.02.010","article-title":"The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study","volume":"180","author":"Pirtle J. L.","year":"2019","unstructured":"J. L. Pirtle, M. D. Hickman, V. C. Boinpelly, K. Surineni, H. K. Thakur, K. W. Grasing, The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study. Pharmacol. Biochem. Behav. 180, 52\u201359 (2019).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/archpsyc.61.3.264","article-title":"Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial","volume":"61","author":"Carroll K. M.","year":"2004","unstructured":"K. M. Carroll, L. R. Fenton, S. A. Ball, C. Nich, T. L. Frankforter, J. Shi, B. J. Rounsaville, Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Arch. Gen. Psychiatry 61, 264\u2013272 (2004).","journal-title":"Arch. Gen. Psychiatry"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drugalcdep.2013.12.007","article-title":"Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment","volume":"136","author":"Schottenfeld R. S.","year":"2014","unstructured":"R. S. Schottenfeld, M. C. Chawarski, J. F. Cubells, T. P. George, J. Lappalainen, T. R. Kosten, Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend. 136, 36\u201342 (2014).","journal-title":"Drug Alcohol Depend."},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drugalcdep.2018.07.025","article-title":"The importance of considering polysubstance use: Lessons from cocaine research","volume":"192","author":"Liu Y.","year":"2018","unstructured":"Y. Liu, V. Williamson, B. Setlow, L. B. Cottler, L. A. Knackstedt, The importance of considering polysubstance use: Lessons from cocaine research. Drug Alcohol Depend. 192, 16\u201328 (2018).","journal-title":"Drug Alcohol Depend."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00205-1"}],"container-title":["Science Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/scitranslmed.adi4505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T16:35:56Z","timestamp":1743611756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.adi4505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":41,"journal-issue":{"issue":"792","published-print":{"date-parts":[[2025,4,2]]}},"alternative-id":["10.1126\/scitranslmed.adi4505"],"URL":"https:\/\/doi.org\/10.1126\/scitranslmed.adi4505","relation":{},"ISSN":["1946-6234","1946-6242"],"issn-type":[{"value":"1946-6234","type":"print"},{"value":"1946-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"2023-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"eadi4505"}}